DBT Bureau
Bengaluru, 7 June
Product engineering firm, Innominds has collaborated with SCIINV Biosciences to introduce AMRx, an AI/ML-driven digital diagnostic tool aimed at addressing the growing threat of antimicrobial resistance (AMR).
The company said that this new will help in changing the detection and treatment of antibiotic-resistant infections by eliminating the need for traditional culture methods.
AMRx, developed by Innominds and SCIINV Biosciences, is a digital diagnostic tool that uses artificial intelligence and machine learning to predict urinary tract infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This technology offers a culture-free approach to diagnosing infections, which can save valuable time and resources, particularly in settings with limited medical infrastructure, the company said in a press release.
Early diagnosis and treatment of infections are critical for improving patient outcomes and reducing the spread of antibiotic-resistant bacteria. According to the company, the tool’s ability to provide timely and accurate diagnoses can play a crucial role in achieving these goals. The adoption of such technology could also alleviate some of the burdens associated with manual record-keeping and traditional diagnostic methods, making healthcare delivery more efficient, it added.
““Innominds is committed to leveraging technology to solve some of the world’s most pressing healthcare challenges,” said Ravi Meduri, Executive Vice President, Digital and IP Solutions, Innominds.
He also said that the partnership with SCIINV Biosciences and the development of AMRx are important steps in the mission to combat antimicrobial resistance and enhance patient care globally.
“Traditional methods are falling short in the race against wildfire like proliferation of antimicrobial resistance. It’s imperative to harness advanced digital technologies (AI/ML/DL) to develop alternative diagnostic tools and therapeutic solutions. Innovative, easily scalable, and quickly implementable digital diagnostic tools and drug development platforms are of paramount importance in the age of devastating pandemics including silent AMR” says Ranga Reddy Burri, Advisor, SCIINV Biosciences Ltd and President, Infection Control Academy of India.
